ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 178,54
0,18%
Dow Jones
44 599,98
-0,25%
DAX
22 513,42
-0,43%
Brent Oil
74,715
-0,50%
Bitcoin
97 344,83
0,75%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTA)

  7. Pasithea Therapeutics Corporation (KTTA) Actualités

KTTA

Pasithea Therapeutics (KTTA)

Pasithea Therapeutics Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KTTA
DateHeureSourceTitreSymboleSociété
06/02/202501h15AllPennyStocks.comBig Mid-Week Move From This Small BiotechNASDAQ:KTTAPasithea Therapeutics Corporation
05/02/202512h59GlobeNewswire Inc.Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNASDAQ:KTTAPasithea Therapeutics Corporation
14/01/202514h02GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4NASDAQ:KTTAPasithea Therapeutics Corporation
27/09/202400h44GlobeNewswire Inc.Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:KTTAPasithea Therapeutics Corporation
26/09/202413h02GlobeNewswire Inc.Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced CancerNASDAQ:KTTAPasithea Therapeutics Corporation
09/09/202414h01GlobeNewswire Inc.Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity StudiesNASDAQ:KTTAPasithea Therapeutics Corporation
03/09/202414h02GlobeNewswire Inc.Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardNASDAQ:KTTAPasithea Therapeutics Corporation
28/08/202415h11GlobeNewswire Inc.Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:KTTAPasithea Therapeutics Corporation
13/08/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTTAPasithea Therapeutics Corporation
13/06/202412h59GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAPasithea Therapeutics Corporation
28/05/202412h59GlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
29/04/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
24/04/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202403h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
13/02/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
18/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
08/01/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAPasithea Therapeutics Corporation
02/01/202414h35GlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323h00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323h00GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAPasithea Therapeutics Corporation
19/12/202323h19GlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
11/12/202314h01GlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202322h27GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202313h59GlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAPasithea Therapeutics Corporation
09/11/202313h59GlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323h01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
16/10/202323h18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202315h15Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202314h30GlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Final Results of Tender OfferNASDAQ:KTTAPasithea Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:KTTA

Dernières Valeurs Consultées

SPI
SP500
S&P 500
EU
RNO
Renault
COIN
DOGEUSD
Dogecoin
NYSE
NKE
Nike
EU
LR
Legrand
NASDAQ
GOOGL
Alphabet
EU
PX4
SBF 120
EU
ACA
Credit Agricole
NYSE
JPM
JP Morgan Chase
COIN
BTCUSD
Bitcoin
EU
ML
Michelin
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces